Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
141.3 USD | +0.89% | -2.12% | +2.47% |
May. 21 | Declaration of Voting Results by Quest Diagnostics Incorporated | CI |
May. 16 | Quest Diagnostics Elects Robert B. Carte to Board of Directors | CI |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The group shows a rather high level of debt in proportion to its EBITDA.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.47% | 15.7B | A- | ||
+17.74% | 83.47B | C+ | ||
-29.66% | 69.72B | B- | ||
-1.06% | 26.5B | C+ | ||
+3.06% | 17.69B | A- | ||
-12.16% | 16.83B | B | ||
+74.82% | 13.45B | C- | ||
+73.52% | 12.81B | C+ | ||
+0.76% | 12.69B | B- | ||
+2.74% | 12.42B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DGX Stock
- Ratings Quest Diagnostics Incorporated